Spots Global Cancer Trial Database for AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Official Title: Phase II Study of 5-Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Study ID: NCT04062266

Conditions

Acute Myeloid Leukemia in Remission

FLT3 Gene Mutation

Hematologic and Lymphocytic Disorder

Acute Myeloid Leukemia

Minimal Residual Disease Persistence

Therapy-Related Acute Myeloid Leukemia

Interventions

Azacitidine

Venetoclax

Study Description

Brief Summary: This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Detailed Description: PRIMARY OBJECTIVES: I. To assess relapse-free survival (RFS) of patients (pts) with acute myeloid leukemia (AML) treated with 5-azacytidine (azacitidine; AZA) combined with venetoclax (VEN) as maintenance therapy after achieving remission. SECONDARY OBJECTIVES: I. To assess modified RFS of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy. II. To assess overall survival (OS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy. III. To assess event-free survival (EFS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy. IV. To assess the duration of remission (CRd) of pts with AML treated 5-azacytidine combined with venetoclax as maintenance therapy. V. To assess toxicity and safety of 5-azacytidine combined with venetoclax as maintenance therapy in pts with AML. VI. To assess the effects of 5-azacytidine combined with venetoclax on dynamics of minimal residual disease (MRD) and their relationship to outcomes. OUTLINE: Patients receive azacitidine subcutaneously (SC) or intravenously (IV) over 1 hour daily on days 1-5, and venetoclax orally (PO) daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 6-12 months thereafter.